Company intelligence / Profile preview
Syntrix Pharmaceuticals
Auburn, Washington, United Statessyntrixbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Syntrix Pharmaceuticals has demonstrated clinical activity with its lead candidate SX‑682—a dual CXCR1/2 inhibitor—in patients with myelodysplastic syndromes who failed front-line hypomethylating agents. The company also has additional assets in pain management and autoimmunity at various stages of development. Its pipeline includes both internally discovered small molecules and externally sourced innovations.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculesBiologics (proteins or antibodies)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with academic researchers such as Dr. Keith Flaherty at Massachusetts General Hospital Cancer Center for clinical trialsgeneral partnerships with research organizations and manufacturers to support R&D and clinical supply chain needs.[5][8]
Beyond the preview
Go deeper on Syntrix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntrix Pharmaceuticals.